evolocumab
amgen
['evolocumab', 'fourier']
#esccongress | fourier-ole: long-term use of the pcsk9 inhibitor evolocumab with median follow-up of more than 7 years led to durable reductions in ldl-c and was both safe and well-tolerated. 
Latest research in cardiology | Breaking news, insights, interviews, live tweeting and updates from major conferences. Co-published by @ilpensiero | @think2it